Pietanza, M. C., Spigel, D., Bauer, T. M., Ready, N. E., Glisson, B. S., Morgensztern, D., … Dylla, S. (2015). 7LBA Safety, activity, and response durability assessment of single agent rovalpituzumab tesirine, a delta-like protein 3 (DLL3)-targeted antibody drug conjugate (ADC), in small cell lung cancer (SCLC). In European Journal of Cancer (Vol. 51, pp. S712–S712). Elsevier BV. https://doi.org/10.1016/s0959-8049(16)31931-1

Pietanza, M. C., D. Spigel, T. M. Bauer, N. E. Ready, B. S. Glisson, D. Morgensztern, F. Robert, et al. “7LBA Safety, activity, and response durability assessment of single agent rovalpituzumab tesirine, a delta-like protein 3 (DLL3)-targeted antibody drug conjugate (ADC), in small cell lung cancer (SCLC).” In European Journal of Cancer, 51:S712–S712. Elsevier BV, 2015. https://doi.org/10.1016/s0959-8049(16)31931-1.

Pietanza MC, Spigel D, Bauer TM, Ready NE, Glisson BS, Morgensztern D, et al. 7LBA Safety, activity, and response durability assessment of single agent rovalpituzumab tesirine, a delta-like protein 3 (DLL3)-targeted antibody drug conjugate (ADC), in small cell lung cancer (SCLC). In: European Journal of Cancer. Elsevier BV; 2015. p. S712–S712.

Pietanza, M. C., et al. “7LBA Safety, activity, and response durability assessment of single agent rovalpituzumab tesirine, a delta-like protein 3 (DLL3)-targeted antibody drug conjugate (ADC), in small cell lung cancer (SCLC).” European Journal of Cancer, vol. 51, Elsevier BV, 2015, pp. S712–S712. Crossref, doi:10.1016/s0959-8049(16)31931-1.

Pietanza MC, Spigel D, Bauer TM, Ready NE, Glisson BS, Morgensztern D, Robert F, Salgia R, Kochendorfer M, Patel M, Strickland DK, Govindan R, Burris HA, Rudin CM, Dylla S. 7LBA Safety, activity, and response durability assessment of single agent rovalpituzumab tesirine, a delta-like protein 3 (DLL3)-targeted antibody drug conjugate (ADC), in small cell lung cancer (SCLC). European Journal of Cancer. Elsevier BV; 2015. p. S712–S712.